Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?

Michael Lübbert, Thomas Büchner, Utz Krug

Journal: Current opinion in hematology 2010;17(2):85-90

PMID: 20061945

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

PURPOSE OF REVIEW

The potential and limitations of the established cytotoxic chemotherapy for acute myeloid leukemia have been assessed by recent large-scale clinical trials. A further progress would require the contribution of alternative approaches.

RECENT FINDINGS

Early results from more specific, less toxic, targeted agents are now available. Major options under investigation are demethylating drugs and inhibitors of tyrosine kinases, farnesylation and angiogenesis.

CONCLUSION

Some of the novel agents, such as demethylating drugs, appear predestined for prolonged maintenance treatment due to their delayed antileukemic mechanism.

Address: Department of Medicine, Hematology/Oncology, University of Münster, Münster, Germany.

DOI: 10.1097/MOH.0b013e3283366bf4

Link outs

Free resources

Medical:

https://medlineplus.gov/acutemyeloidleukemia.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Azacitidine, Benzenesulfonates, Decitabine, Enzyme Inhibitors, Humans, Leukemia, Myeloid, Acute, Niacinamide, Phenylurea Compounds, Prenylation, Protein-Tyrosine Kinases, Pyridines, Sorafenib, Staurosporine